Similar Search Results

The impact of Medicare Part D on Medicare-Medicaid dual-eligible benficiaries' prescription utilization and expenditurs

Basu, Anirban; Yin, Wesley; Alexander, G. Caleb - 2008

Persistent link: https://www.econbiz.de/10003770583

The Impact of Medicare Part D on Medicare-Medicaid Dual-Eligible Beneficiaries' Prescription Utilization and Expenditures

Basu, Anirban - 2008

Features of Part D gave rise to broad concern that the drug benefit would negatively impact prescription utilization among the six million dual eligible beneficiaries, either during the transition from state Medicaid to Part D coverage, or in the long-run. At the same time, Part D contained...

Persistent link: https://www.econbiz.de/10012769646

Personalized medicine in the context of comparative effectiveness research

Basu, Anirban - In: Forum for health economics & policy : an evolving … 16 (2013) 2, pp. 73-86

Persistent link: https://www.econbiz.de/10009779114

The impact of Medicare Part D on Medicare-Medicaid Dual-eligible Beneficiaries' Prescription Utilization and Expenditures

Basu, Anirban - 2008

Persistent link: https://www.econbiz.de/10012464234

Price elasticities of pharmaceuticals in a value-based-formulary setting

Yeung, Kai; Basu, Anirban; Hansen, Ryan N.; Sullivan, … - 2016

Persistent link: https://www.econbiz.de/10011495052

Price Elasticities of Pharmaceuticals in a Value-Based-Formulary Setting

Yeung, Kai - 2016

pharmaceuticals, are deemed to be price inelastic with price elasticities of demand (PED) close to -0.20. However, most studies of PED … designed based on drug-specific incremental cost-effectiveness ratios, we estimate price elasticities of pharmaceuticals within … produce positive welfare effects. We estimate an overall PED for pharmaceuticals to be -0.16, close to the estimate of RAND …

Persistent link: https://www.econbiz.de/10012989727

The New Prescription Drug Paradox : Pipeline Pressure and Rising Prices

Ellyson, Alice - 2018

Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...

Persistent link: https://www.econbiz.de/10012925274

Health economics tools and precision medicine : opportunities and challenges

Veenstra, David L.; Mandelblatt, Jeanne S.; Neumann, Peter - In: Forum for health economics & policy : an evolving … 23 (2020) 1, pp. 1-14

Persistent link: https://www.econbiz.de/10012299489

Returns to pharmaceutical innovation in the market for oral chemotherapy in response to insurance coverage expansion

Bennette, Caroline S.; Basu, Anirban; Ramsey, Scott; … - 2017

Persistent link: https://www.econbiz.de/10011743344

The new prescription drug paradox : pipeline pressure and rising prices

Ellyson, Alice M.; Basu, Anirban - 2018

Persistent link: https://www.econbiz.de/10011821726